Literature DB >> 9143865

Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrénées.

M Lapeyre-Mestre1, C Damase-Michel, P Adams, P Michaud, J L Montastruc.   

Abstract

OBJECTIVE: While data on drug abuse liability have been determined for selected drugs in experimental studies, there is limited information available about drug abuse in real life. This study presents the results of a simple experimental epidemiologic survey of prescription forgeries in community pharmacies in the Midi-Pyrénées area (southwest France). During four periods (September-October 1991, January-June 1992, September-October 1992 and January-June 1993), resident pharmacy students in several volunteer pharmacies were asked to complete a specific report form for each suspect prescription request. The main criteria used to identify forgeries were: inadequate dosage, multiple use of the prescription form, drafting not in accordance with the rules of prescription or false prescription forms (stolen prescription forms, photocopies).
RESULTS: A total of 165 falsified prescriptions were collected. The 305 drugs involved in these forged prescriptions were opiate analgesics, benzodiazepines, amphetamines and minor opiate analgesics. Medications were essentially buprenorphine, flunitrazepam (in 2 mg dosage), phenobarbitone+amphetamine and chlorazepate.
CONCLUSION: These results suggest that forged prescriptions can be used as an indicator of potential abuse liability of marketed psychoactive drugs. Although this survey cannot describe the real prevalence of the misuse or abuse of drugs, it constitutes a useful warning epidemiologic system to elicit early observations regarding new misuses of drugs as they are requested at the pharmacy.

Entities:  

Mesh:

Year:  1997        PMID: 9143865     DOI: 10.1007/s002280050246

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

Review 1.  Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey.

Authors:  Caroline Victorri-Vigneau; Eric Dailly; Gwenaëlle Veyrac; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

2.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

3.  Multicentre study for validation of the French addictovigilance network reports assessment tool.

Authors:  Caroline Victorri-Vigneau; Jean Benoit Hardouin; Morgane Rousselet; Marie Gerardin; Marylène Guerlais; Morgane Guillou; Marie Bronnec; Véronique Sébille; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

Review 4.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

5.  Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey.

Authors:  Olivia Boeuf; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.